{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:20:18Z","timestamp":1789600818533,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill &amp; Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jvacx.2022.100143","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T10:59:40Z","timestamp":1644058780000},"page":"100143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial"],"prefix":"10.1016","volume":"10","author":[{"given":"K.","family":"Zaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md.","family":"Yunus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma B.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Feser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon W.","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Butsaya","family":"Thaisomboonsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Marfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. William","family":"Letson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jvacx.2022.100143_b0005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.15585\/mmwr.mm6622a3","article-title":"Japanese Encephalitis Surveillance and Immunization \u2014 Asia and Western Pacific Regions, 2016","volume":"66","author":"Heffelfinger","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jvacx.2022.100143_b0010","article-title":"Viral etiology of encephalitis in children in Southern Vietnam: Results of a one-year prospective descriptive study","volume":"4","author":"van Tan","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.jvacx.2022.100143_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2403-z","article-title":"Viral aetiologies of acute encephalitis in a hospital-based South Asian population","volume":"17","author":"Lohitharajah","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.jvacx.2022.100143_b0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7883\/yoken.67.197","article-title":"Epidemiology and etiology of acute encephalitis syndrome in North India","volume":"67","author":"Jain","year":"2014","journal-title":"Jpn J Infect Dis"},{"issue":"10","key":"10.1016\/j.jvacx.2022.100143_b0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: A systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"issue":"5","key":"10.1016\/j.jvacx.2022.100143_b0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrneurol.2018.30","article-title":"Japanese encephalitis-the prospects for new treatments","volume":"14","author":"Turtle","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jvacx.2022.100143_b0035","doi-asserted-by":"crossref","unstructured":"Halstead SB, Hills SL, Dubischar K. 33 - Japanese Encephalitis Vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KMBT-PV, Seventh E, editors., Elsevier; 2018, p. 511\u2013548.e12. htpp:\/\/dx.doi.10.1016\/B978-0-323-35761-6.00033-X.","DOI":"10.1016\/B978-0-323-35761-6.00033-X"},{"issue":"13","key":"10.1016\/j.jvacx.2022.100143_b0040","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.vaccine.2020.02.018","article-title":"Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies","volume":"38","author":"Vodicka","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2022.100143_b0045","article-title":"Japanese Encephalitis Vaccines: WHO position paper, February 2015 - Recommendations","volume":"34","author":"World Health Organization","year":"2016","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.jvacx.2022.100143_b0050","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1016\/j.vaccine.2014.09.012","article-title":"Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product","volume":"32","author":"Zaman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2022.100143_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005866","article-title":"Updated estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14\u201314-2 vaccine in Nepal","volume":"11","author":"Upreti","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"27","key":"10.1016\/j.jvacx.2022.100143_b0060","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2007.04.052","article-title":"Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization","volume":"25","author":"Tandan","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jvacx.2022.100143_b0065","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jinf.2014.06.017","article-title":"Low coverage and acceptable effectiveness of single dose of Japanese encephalitis vaccine, Gorakhpur division, Uttar Pradesh, India, 2013","volume":"69","author":"Murhekar","year":"2014","journal-title":"J Infect"},{"issue":"9015","key":"10.1016\/j.jvacx.2022.100143_b0070","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0140-6736(96)91075-2","article-title":"Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): A case-control study","volume":"347","author":"Hennessy","year":"1996","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.jvacx.2022.100143_b0075","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.vaccine.2008.01.021","article-title":"A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses","volume":"26","author":"Sohn","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2022.100143_b0080","unstructured":"WHO Multicentre Growth Reference Study Group (2006). WHO Child Growth Standards: Length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva; 2006."},{"key":"10.1016\/j.jvacx.2022.100143_b0085","unstructured":"US Department of Health and Human Services. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0. Div AIDS Natl Inst Allergy Infect Dis Natl Inst Haelth Hum Serv; 2014."},{"issue":"4","key":"10.1016\/j.jvacx.2022.100143_b0090","doi-asserted-by":"crossref","first-page":"418","DOI":"10.4269\/ajtmh.1989.40.418","article-title":"An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate","volume":"40","author":"Suntayakorn","year":"1989","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.jvacx.2022.100143_b0095","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4269\/ajtmh.2009.08-0625","article-title":"Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance","volume":"81","author":"Jarman","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2022.100143_b0100","unstructured":"SEATO Medical Research Laboratory. SEATO Annual Report. JEV Plaque-Reduction Neutralization Test (PRNT): A Statistical Evaluation; 1971."},{"issue":"45","key":"10.1016\/j.jvacx.2022.100143_b0105","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2022.100143_b0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4049\/jimmunol.86.2.151","article-title":"The anamnestic antibody response to Japanese encephalitis virus in monkeys and its implications concerning naturally acquired immunity in man","volume":"86","author":"Lee","year":"1961","journal-title":"J Immunol"},{"key":"10.1016\/j.jvacx.2022.100143_b0115","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/INF.0000000000001494","article-title":"Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization","volume":"36","author":"Kosalaraksa","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.jvacx.2022.100143_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","article-title":"Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Hills","year":"2019","journal-title":"MMWR Recomm Rep"},{"issue":"18","key":"10.1016\/j.jvacx.2022.100143_b0125","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/S0264-410X(99)00006-7","article-title":"Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants","volume":"17","author":"Sohn","year":"1999","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jvacx.2022.100143_b0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Marchesani","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jvacx.2022.100143_b0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","article-title":"Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection","volume":"56","author":"Reinhardt","year":"1998","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.jvacx.2022.100143_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0205-6","article-title":"Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection","volume":"5","author":"Staples","year":"2020","journal-title":"npj Vaccines"},{"issue":"2","key":"10.1016\/j.jvacx.2022.100143_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biologicals.2007.07.002","article-title":"Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines - Report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies","volume":"36","author":"Ferguson","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.jvacx.2022.100143_b0150","first-page":"11","article-title":"Measles prevention: supplementary statement","volume":"38","author":"Centers for Disease Control (CDC)","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136222000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136222000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:05:33Z","timestamp":1762913133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136222000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":30,"alternative-id":["S2590136222000031"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2022.100143","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2022.100143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100143"}}